Fruquintinib as Maintenance Therapy for Colorectal Liver Metastases: A Potential Breakthrough

Background: The 5-year survival rate for patients with colorectal liver metastases (CRLM) remains low, with high rates of recurrence even after surgery and adjuvant therapy. Fruquintinib, a highly selective anti-angiogenic inhibitor, has shown promise in treating advanced colorectal cancer (CRC).

Objective: This study aims to evaluate the clinical efficacy and safety of fruquintinib as maintenance therapy following adjuvant chemotherapy in patients with advanced CRC who have achieved NED.

Methods: This study will enroll patients with advanced CRC and CRLM who have undergone surgery and adjuvant chemotherapy and achieved NED. Patients will be randomized to receive either fruquintinib or placebo as maintenance therapy. The primary endpoint will be disease-free survival, while secondary endpoints will include overall survival, time to recurrence, safety, and quality of life.

Significance: This study will provide valuable insights into the potential of fruquintinib as a maintenance therapy option for patients with CRLM. If successful, fruquintinib could significantly improve long-term outcomes for these patients by reducing recurrence rates and prolonging survival.

Key Highlights:* CRLM is associated with a poor prognosis, with high recurrence rates despite surgery and adjuvant therapy.* Fruquintinib is a promising anti-angiogenic inhibitor with a favorable safety profile.* This study will evaluate the efficacy and safety of fruquintinib as maintenance therapy in patients with CRLM who have achieved NED.* Positive results could establish fruquintinib as a new standard of care for these patients, potentially leading to significant improvements in survival and quality of life.